The increase of IL-17 in MISC_A patients could raise awareness for more future studies on novel diagnostic assays and treatment strategies involving IL-17-targeted biologic therapies, such as Secukinumab, Bimekizumab, Brodamulab, and Ixekizumab, which have already effectively been used in other IL-17-mediated conditions, such as Crohn’s disease, psoriasis, and ankylosing spondylitis [37]. This evidence concerns the gene IL17A and ankylosing spondylitis.